New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy
A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy
PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma
A new study suggests that drugs known as PARP inhibitors may enhance immunotherapy response in mesothelioma patients. According to a report published in the Journal of Clinical Investigations, PARP inhibitors worked especially well in cancers with mutations in their DNA repair genes. Some malignant mesothelioma patients have mutated DNA repair genes. In these patients, a PARP inhibitor may modify immunotherapy response, making drugs like Keytruda work better. How PARP Impacts Immunotherapy Response PARP stands for poly (ADP-ribose) polymerase. It represents a family of proteins involved in a number of cellular processes, including DNA repair. PARP is also involved in apoptosis, or programmed cell death. Olaparib (Lynparza) is an example of a PARP inhibitor. PARP inhibitors attack tumors that already have … Continue reading PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma
Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy
New metadata suggests that intrapleural immunotherapy is a powerful, targeted way to treat malignant pleural mesothelioma. Pleural mesothelioma is a deadly cancer of the lining around the lungs. It is caused by asbestos exposure and is notoriously difficult to treat. Now, a new study suggests that delivering immunotherapy treatments directly into the pleural space where mesothelioma tumors form may help these drugs work even better. What is Intrapleural Immunotherapy? Immunotherapy treatments harness the immune system to help fight cancer. Immunotherapy works alone or in combination with other treatments like chemotherapy or surgery. Many researchers and doctors believe that immunotherapy is the future of mesothelioma treatment. Intrapleural immunotherapy is a more targeted way to deliver these cancer-fighting messengers. It does … Continue reading Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy
New Mesothelioma Immunotherapy Treatment Reduces Tregs with Immunotoxin
There is a new mesothelioma immunotherapy treatment in the works. This one is based on reducing the number of Tregs or regulatory T-cells around a mesothelioma tumor. Tregs are an important part of maintaining balance in the immune system. They help protect people against autoimmune diseases like MS and lupus. But in people with malignant mesothelioma and other types of cancer, too many Tregs can be a problem. Tregs respond to distress signals sent out by a tumor. They surround the tumor and protect it against attack from the immune system. The goal of mesothelioma immunotherapy treatment is to reactivate the immune system to fight the cancer. Developing a Mesothelioma Immunotherapy Treatment Molecular biologists at the National Cancer Institute and … Continue reading New Mesothelioma Immunotherapy Treatment Reduces Tregs with Immunotoxin
New Mesothelioma Drug Trial Begins
A new mesothelioma drug trial is now underway. The trial will test a brand new type of immunotherapy medication called CA-170. CA-170 is designed to block an immune system suppressor called VISTA. It is the only VISTA-blocking medication currently in clinical trial. “CA-170 has demonstrated favorable safety and tolerability as well as preliminary anti-tumor activity in patients across multiple tumor types,” the company said in a statement. Mesothelioma Drug Trial Focuses on VISTA Malignant mesothelioma is highly resistant to standard cancer treatments. Many top researchers believe that immunotherapy drugs offer the best promise for curing mesothelioma. That is because cancers like malignant mesothelioma survive in part by evading detection by the immune system. They do this in a variety ways … Continue reading New Mesothelioma Drug Trial Begins
Avelumab May Offer a Second-Line Option for Recurrent Mesothelioma
People with recurrent mesothelioma may get another chance at treatment with the immunotherapy drug avelumab. Malignant mesothelioma is highly resistant to standard cancer therapies. That means that the asbestos cancer usually comes back, or recurs, even after treatment. The most common treatment for mesothelioma is chemotherapy with Alimta. Alimta is the only drug approved specifically for mesothelioma. Patients with recurrent mesothelioma often have several rounds of chemotherapy with Alimta. But once the standard mesothelioma treatments stop working, patients do not have many options. Now a new study suggests that some cases of recurrent mesothelioma that stop responding to Alimta may respond to avelumab. Considering Avelumab for Recurrent Mesothelioma Bavencio is the brand name for avelumab. It is a type … Continue reading Avelumab May Offer a Second-Line Option for Recurrent Mesothelioma
Virotherapy for Mesothelioma Can Be More Effective
Hong Kong researchers may have found a way to get around one of the biggest challenges of virotherapy for mesothelioma. Virotherapy uses a modified virus to deliver medicine or genetic information into the body. Modified viruses are useful because they can be “programmed” to seek out cancer cells. But modified viruses do not always behave the way scientists hope they will. One problem with some virotherapy for mesothelioma is that it can block the natural immune response. The body naturally fights malignant mesothelioma by releasing white blood cells called CTLs (T lymphocytes). But MVTT virotherapy can prevent the release of CTLs, even while it attacks the tumor. “Although MVTT [a type of virotherapy] leads to regression of established mesothelioma dose-dependently, … Continue reading Virotherapy for Mesothelioma Can Be More Effective
Immunotherapy for Peritoneal Mesothelioma: New Drug Trial Begin
Researchers in Maryland and Missouri have started human testing of a new type of immunotherapy for peritoneal mesothelioma. If the human trial of this new CAR T-cell therapy goes as well as the laboratory tests, this could be good news for many people with asbestos cancer. CAR stands for chimeric antigen receptor. CAR T-cell therapy works by “reprogramming” a patient’s immune system to fight cancer cells. Tests show this therapy can work well for blood-based cancers like leukemia. But the results have not been as good for solid tumors like peritoneal mesothelioma. MaxCyte is the American company than makes the new drug. They are hoping that their approach to immunotherapy for peritoneal mesothelioma will be better. Preparing CAR T-cell Therapy … Continue reading Immunotherapy for Peritoneal Mesothelioma: New Drug Trial Begin
Radiation May Help Mesothelioma Immunotherapy Treatment Work Better
Hypofractionated radiation for mesothelioma could change how doctors treat this rare cancer. Researchers in Toronto, Canada have been testing hypofractionated radiation in mesothelioma surgery patients. They have used it to shrink tumors before lung-removing EPP surgery. Hypofractionated radiation is faster than than standard radiation. It may also cause fewer side effects. Now, doctors want to know what else this type of radiation might be good for. They plan to test how well hypofractionated radiation works with less radical mesothelioma surgery. There is also evidence that hypofractionated radiation may strengthen mesothelioma immunotherapy treatment. Radiation Before Mesothelioma Surgery Doctors at the Princess Margaret Cancer Center in Toronto ran a clinical trial called SMART. SMART stands for Surgery for Mesothelioma After Radiation Therapy. … Continue reading Radiation May Help Mesothelioma Immunotherapy Treatment Work Better
Study Predicts New Mesothelioma Therapies on the Horizon
A new article published by a pair of UK scientists predicts a brighter future for mesothelioma patients thanks to a growing understanding of the disease and how to treat it. Malignant mesothelioma is the cancer most closely associated with asbestos. Although only a small percentage of asbestos-exposed people go on to develop mesothelioma, those who do face a grim prognosis. Doctors learned early on that standard cancer treatments rarely work for patients with mesothelioma. But Anna Bibby and Nick Maskell with Bristol Medical School and the North Bristol Lung Centre say the large amount of high-quality mesothelioma research conducted in the last decade has moved medicine closer to finding a cure for this intractable cancer. Important Mesothelioma Research Findings In … Continue reading Study Predicts New Mesothelioma Therapies on the Horizon
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!